Risk score for predicting death, myocardial infarction and stroke in patients with stable angina, based on a large randomised trial cohort of patients.
Clayton T, Lubsen J, Pocock SJ, et al, on behalf of the ACTION investigators. BMJ 2005; 331;869–73. ACTION provides a risk scoring system for patients with angina.
Read more…
Safety of nifedipine GITS in stable angina: the ACTION trial
Poole-Wilson PA, Kirwan BA, Vokó Z, et al, on behalf of the ACTION investigators. Cardiovasc Drugs Ther 2006;20:45–54..
ACTION strengthens the evidence that Adalat® (nifedepine GITS) is well tolerated in patients with symptomatic stable angina and coronary artery diease.
Read more…
Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease.
Otterstad JE, Kirwan, B-A, Lubsen J, et al, on behalf of the ACTION investigators. Scan Cardiovasc J
2006;40:152–9.
Patients with coronary qartery disease and atrial fibrillation benefit from therapy with Adalat® (nifedipine GITS).
Read more…
Tracking coronary calcification and atherosclerotic lesions in patients with stable angina pectoris undergoing nifedipine therapy.
Motro M, Kirwan B-A, de Brouwer S, et al. Cardiology 2007;107:166–71.
Early intervention with Adalat® (nifedipine GITS) can slow the development of new atherosclerotic lesions in patients with coronary artery disease. Furthermore, Adalat® has beneficial effects on the development of new or early atherosclerotic lesions.
Read more…
The development of heart failure in patients with stable angina pectoris.
Sutton GC, Otterstad JE, Kirwan B-A, et al, on behalf of the ACTION investigators. Eur J Heart
Failure 2006; doi:10.1016/j.ejheart.2006.09.002
Adalat® (nifedipine GITS) significantly reduces the risk of new overt heart failure.
Read more…
Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions.
Lubsen J, Vokó Z, Poole-Wilson PA, et al, on behalf of the ACTION Investigators. J Clin Epidemiol;2007 doi:10.1016/j.jclinepi.2006.10.015
Adalat® (nifedipine GITS) significantly reduces the incidence of debilitating stroke and heart failure through its BP-lowering effects
Read more…
Resource utilisation implications of treatment can be assessed when clinical trial data are reported appropriately.
Poole-Wilson PA, Kirwan B-A, Vokó Z, et al, on behalf of the ACTION Investigators. J Clin Epidemiol; doi:10.1016/j.jclinepi.2006.10.016
In patients with symptomatic stable angina and coronary artery disease, Adalat® (nifedipine GITS) significantly reduces the need for costly medical and procedural interventions – reducing the burden on healthcare resources.
Read more…